logo
  

Kulicke & Soffa Industries Inc. Q2 Earnings Summary

Below are the earnings highlights for Kulicke & Soffa Industries Inc. (KLIC):

Earnings: -$102.68 million in Q2 vs. $15.04 million in the same period last year.
EPS: -$1.83 in Q2 vs. $0.26 in the same period last year.
Excluding items, Kulicke & Soffa Industries Inc. reported adjusted earnings of -$53.25 million or -$0.95 per share for the period.

Analysts projected $0.24 per share
Revenue: $172.07 million in Q2 vs. $173.02 million in the same period last year.

-Guidance:
Next quarter EPS guidance: $0.27 - $0.33
Next quarter revenue guidance: $170 - $190 Mln

For comments and feedback contact: editorial@rttnews.com

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT